Bluebird Bio Inc. (NASDAQ:BLUE)’s share price rose 4.2% during trading on Tuesday . The company traded as high as $74.74 and last traded at $73.96, with a volume of 837,137 shares traded. The stock had previously closed at $70.95.

A number of brokerages have recently issued reports on BLUE. Wedbush reissued an “outperform” rating and issued a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $135.00 target price on shares of Bluebird Bio in a research report on Thursday, September 8th. Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a research report on Monday, June 13th. Piper Jaffray Cos. set a $95.00 target price on shares of Bluebird Bio and gave the company a “buy” rating in a research report on Thursday, September 8th. Finally, Vetr cut shares of Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 target price for the company. in a research report on Wednesday, June 8th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $87.39.

The firm’s market capitalization is $2.74 billion. The company has a 50-day moving average of $57.02 and a 200 day moving average of $48.11.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. During the same period in the prior year, the business earned ($1.57) earnings per share. The company’s revenue for the quarter was down 68.6% compared to the same quarter last year. On average, analysts forecast that Bluebird Bio Inc. will post ($6.16) EPS for the current year.

In related news, insider Eric Sullivan sold 2,912 shares of Bluebird Bio stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total value of $160,189.12. Following the completion of the sale, the insider now owns 4,456 shares of the company’s stock, valued at approximately $245,124.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $45.08, for a total value of $45,080.00. Following the completion of the sale, the insider now directly owns 10,600 shares of the company’s stock, valued at approximately $477,848. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. RTW Investments LLC purchased a new stake in shares of Bluebird Bio during the first quarter valued at $9,621,000. JPMorgan Chase & Co. raised its stake in shares of Bluebird Bio by 7.0% in the first quarter. JPMorgan Chase & Co. now owns 59,623 shares of the company’s stock valued at $2,535,000 after buying an additional 3,906 shares during the period. Clarius Group LLC purchased a new stake in shares of Bluebird Bio during the first quarter valued at $410,000. BlackRock Group LTD raised its stake in shares of Bluebird Bio by 11.2% in the first quarter. BlackRock Group LTD now owns 24,672 shares of the company’s stock valued at $1,049,000 after buying an additional 2,493 shares during the period. Finally, BlackRock Inc. raised its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the period.

Bluebird Bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.